Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer

• Published in: Oncotarget Vol. 8; no. 52; pp. 90557 - 90578
• Main Authors: Xu, Jing, Wang, Jinghui, Zhang, Shucai
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 27.10.2017
• Subjects: Review; irreversible EGFR-TKIs; NSCLC; mechanisms; resistance; therapeutic strategies
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.21164

Epidermal growth factor receptor (EGFR) T790M mutation is the most frequent mechanism which accounts for about 60% of acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutations. Irreversible EGFR-TKIs which include the second-generation and third-generation EGFR-TKIs are developed to overcome T790M mediated resistance. The second-generation EGFR-TKIs inhibit the wide type (WT) EGFR combined with dose-limiting toxicity which limits its application in clinics, while the development of third-generation EGFR-TKIs brings inspiring efficacy either or . The acquired resistance, however, will also occur and limit their response. Understanding the mechanisms of resistance to irreversible EGFR-TKIs plays an important role in the choice of subsequent treatment. In this review, we show the currently known mechanisms of resistance which can be summarized as EGFR dependent and independent mechanisms and potential therapeutic strategies to irreversible EGFR-TKIs.